A Phase 3 interventional study of Pegylated interferon alfa-2b and Ribavirin in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing peginterferon alfa-2b in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C.
Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, this one is the 11th largest by enrollment, is the only one that started in 2003, is one of 7 in phase 3, and was the 11th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 23 studies testing peginterferon alfa-2b in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 9 · Phase 4 6
First in 1997; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 102 across the 23 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
92 studies in Hepatitis C by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 86 finished, 66 (77%) have results posted.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 19th largest by enrollment of the 69 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 3, and was the 5th registered.
Merck & Co., Inc’s Hepatitis C studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 92 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C. After 12 weeks of observation from disease onset, participants will receive one of the following regimens: (1) a 24-week course of PEG-IFN monotherapy (PEG-IFN 24); or (2) a 12-week course of PEG-IFN monotherapy (PEG-IFN-12); or (3) a 12-week course of PEG-IFN in combination with ribavirin (PEG-IFN + RVB 12). After the treatment period, participants will enter a 12-month follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
Biological: Pegylated interferon alfa-2b
pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
Biological: Pegylated interferon alfa-2b
pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Biological: Pegylated interferon alfa-2b · Drug: Ribavirin
1.5 ug/kg/week SC for 12 or 24 weeks
Also known as: SCH 54031, PegIntron
Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Also known as: SCH 18908, Rebetol
Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period
SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.
Time frame: Evaluated at the end of 6 months
Virologic Response at the End of Treatment Follow-up (ETR)
ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks treatment (depending on treatment arm) was \<15 IU/mL.
Time frame: At the end of treatment (either 12 weeks or 24 weeks depending on randomization).
Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).
LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was \<15 IU/mL.
Time frame: At 12 months post-treatment (treatment period either 12 weeks or 24 weeks depending on randomization).
Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization
ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.
Time frame: Evaluated at end of treatment (either 12 weeks or 24 weeks, depending on randomization), at 6-month follow-up visit, or at 12-month follow-up visit.
Number of Participants With Rapid Virologic Response (RVR)
Participants were considered to have RVR if serum HCV RNA level at 2 or 4 weeks of treatment was below the cut off value of the referring local laboratory of each participating site.
Time frame: Evaluated at 2 and 4 weeks of treatment
Number of Peripheral Blood Mononuclear Cells (PBMCs)
Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.
Time frame: Treatment Weeks 2, 4, 8, and 12
| Milestone | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| Started | 44 | 43 | 43 |
| Completed final treatment visit | 44 | 43 | 43 |
| Completed | 38 | 40 | 42 |
| Not completed | 6 | 3 | 1 |
| Withdrew: Serious adverse event | 1 | 2 | 1 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Poor protocol compliance | 1 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Milestone | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| Started | 37 | 38 | 39 |
| Completed | 29 | 28 | 29 |
| Not completed | 8 | 10 | 10 |
SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.
| participants | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period | 23 | 20 | 21 |
ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks treatment (depending on treatment arm) was \<15 IU/mL.
| participants | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| Virologic Response at the End of Treatment Follow-up (ETR) | 26 | 28 | 27 |
LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was \<15 IU/mL.
| participants | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]). | 20 | 19 | 19 |
ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.
| participants | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| End of Treatment | 28 | 31 | 32 |
| 6-month Follow-up Period | 31 | 27 | 28 |
| 12-month Follow-up Period | 27 | 23 | 23 |
Participants were considered to have RVR if serum HCV RNA level at 2 or 4 weeks of treatment was below the cut off value of the referring local laboratory of each participating site.
| participants | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 |
|---|---|---|---|
| 2 weeks after start of treatment | 24 | 25 | 23 |
| 4 weeks after start of treatment | 28 | 35 | 34 |
Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN 12 | — | 3/43 (7%) | 37/43 (86%) |
| PEG-IFN 24 | — | 4/44 (9.1%) | 43/44 (97.7%) |
| PEG-IFN + RVB 12 | — | 4/43 (9.3%) | 42/43 (97.7%) |
| Event | PEG-IFN 12 | PEG-IFN 24 | PEG-IFN + RVB 12 |
|---|---|---|---|
| HypoAcusisEar and labyrinth disorders | 1/43 | 0/44 | 0/43 |
| DacryocystitisInfections and infestations | 0/43 | 0/44 | 1/43 |
| Transaminases IncreasedInvestigations | 1/43 | 0/44 | 0/43 |
| Lung Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/44 | 1/43 |
| HeadacheNervous system disorders | 1/43 | 0/44 | 0/43 |
| Optic NeuritisNervous system disorders | 0/43 | 0/44 | 1/43 |
| ManiaPsychiatric disorders | 0/43 | 0/44 | 1/43 |
| Autoimmune thyroiditisEndocrine disorders | 0/43 | 1/44 | 0/43 |
| DiarrheaGastrointestinal disorders | 0/43 | 1/44 | 0/43 |
| VomitingGastrointestinal disorders | 0/43 | 1/44 | 0/43 |
| Event | PEG-IFN 12 | PEG-IFN 24 | PEG-IFN + RVB 12 |
|---|---|---|---|
| GranulocytopeniaBlood and lymphatic system disorders | 22/43 | 32/44 | 26/43 |
| LeukopeniaBlood and lymphatic system disorders | 31/43 | 30/44 | 31/43 |
| PyrexiaGeneral disorders | 27/43 | 30/44 | 28/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/43 | 13/44 | 13/43 |
| HeadacheNervous system disorders | 11/43 | 13/44 | 12/43 |
| AstheniaGeneral disorders | 12/43 | 11/44 | 7/43 |
| PainGeneral disorders | 8/43 | 9/44 | 7/43 |
| Transaminases IncreasedInvestigations | 4/43 | 8/44 | 2/43 |
| Platelet Count DecreasedInvestigations | 7/43 | 5/44 | 1/43 |
| NauseaGastrointestinal disorders | 2/43 | 7/44 | 3/43 |
| Age, Continuous(years) | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 | Total |
|---|---|---|---|---|
| Mean | 36.55 ± 13.86 | 38.32 ± 13.95 | 38.52 ± 12.48 | 37.79 ± 13.37 |
| Sex: Female, Male(Participants) | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 | Total |
|---|---|---|---|---|
| Female | 15 | 16 | 6 | 37 |
| Male | 29 | 27 | 37 | 93 |
| Region of Enrollment(participants) | PEG-IFN 24 | PEG-IFN 12 | PEG-IFN + RVB 12 | Total |
|---|---|---|---|---|
| Italy | 44 | 43 | 43 | 130 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Dec 2003, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b